Clinical-stage pharmaceutical developer of TRPM8 agonist therapeutics targeting patients with chronic cough and dry eye disorders. Rapid-onset, topical small-molecule programs aimed at normalizing abnormal cough and lacrimation reflexes with clinical proof-of-concept, safety data, and a lead candidate advancing toward Phase 2b.